Anacor tops the mid-cap space
Considering the mid-cap stocks across different healthcare ETFs, Anacor Pharmaceuticals (ANAC) outperformed other mid-cap stocks. The company has a market cap of ~$4.63 billion. The iShares Nasdaq Biotechnology ETF (IBB) invests ~0.9% of its portfolio in Anacor. Additionally, the SPDR S&P Biotech ETF (XBI) invests 1.1% in Anacor. The company gave a YTD (year-to-date) return of 225.6% as on November 12, 2015. Peers include Allergan (AGN), Mallinckrodt Public (MNK), and Endo International (ENDP). The three gave YTD returns of 16.5%, -46%, and -22.2%, respectively.
The graph above reflects the performance of Anacor in comparison with Allergan, Mallinckrodt, Endo, and the SPDR S&P 500 ETF (SPY) on a month-over-month basis until October 31, 2015. Out of ten months, Anacor gave positive returns for six and negative returns for four. The best performance came in July 2015, with a return of 92.6%. On the other hand, the worst performance came in the month of September 2015, with a return of -9.8%.
On November 12, 2015, Anacor closed at $105.0 and was trading below the 20-, 50-, and 100-day moving averages. The book value of Anacor is $1.6 per share and with its current price, the stock is trading at a price-to-book value ratio of 65.83x.
What drove Anacor to surge?
Anacor’s revenue has been growing in 2015 on a quarter-over-quarter basis primarily due to KERYDIN under the agreement with Sandoz. Another major factor was the positive results from its Phase 3 clinical trial of Crisaborole Topical Ointment, 2% in patients with mild-to-moderate atopic dermatitis. Anacor expects to submit a New Drug Application for Crisaborole topical ointment, 2%, to the US Food and Drug Administration in the first quarter of 2016.